Form 4: Gilead Sciences Chief Commercial Officer Sells Shares Under Pre-Arranged Trading Plan

Gilead Sciences' Chief Commercial Officer, Johanna Mercier, sold 3,000 shares of common stock for $110.17 per share on June 16, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Johanna Mercier, Chief Commercial Officer of Gilead Sciences, Inc. (GILD), reported a sale of company common stock.
• The transaction involved the disposition of 3,000 shares of common stock.
• The shares were sold at a price of $110.17 per share.
• The transaction occurred on June 16, 2025.
• Following this transaction, Ms. Mercier beneficially owns 120,168 shares of Gilead Sciences common stock.
• The sale was executed pursuant to a Rule 10b5-1 trading plan, which was adopted on February 20, 2025.

Sentiment

Score: 5

Explanation: Neutral, as it reports a pre-scheduled insider transaction rather than new company performance data or strategic developments.

Positives

• The transaction was conducted under a Rule 10b5-1 trading plan, adopted on February 20, 2025, indicating a pre-scheduled sale not based on new, non-public information, which enhances transparency and reduces concerns about opportunistic insider trading.

Negatives

• The sale by a Chief Commercial Officer reduces the insider's direct ownership stake in the company, which some investors might interpret as a slight negative, despite being pre-planned.

Future Outlook

This Form 4 filing reports a past insider transaction and does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This filing is a standard disclosure of an insider stock transaction and does not provide information related to broader industry trends or competitive landscape analysis.

Stakeholder Impact

• Shareholders: May view the sale as a routine, pre-planned transaction given the 10b5-1 plan, or as a minor reduction in insider alignment, depending on individual interpretation.

Key Dates

Keywords

Gilead Sciences, GILD, insider trading, Form 4, stock sale, Johanna Mercier, Chief Commercial Officer, 10b5-1 plan